SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp neocloud and AI-infrastructure selloff, as concerns about financing costs, debt sustainability and returns on the sectors buildout spill over from CoreWeave credit worries. Traders are divided on the rebound, with some seeing an oversold buying opportunity and others calling it a bull trap that could give way to further declines.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs stronger-than-guided Q3 results and upbeat 2027 EBITDA outlook have driven a sharp share-price rebound. Bulls are discussing potential short covering, while skeptics question whether operating improvements and steel prices can support the outlook given the companys debt.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-approved expansion of Alpha Taus REGAIN trial for recurrent glioblastoma, alongside planned SNO data presentation, is driving attention; traders are upbeat about the early results and a larger patient cohort, while further evidence is still pending. The community also points to upcoming pancreatic and other clinical milestones as potential catalysts.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade of CoreWeave to Buy is driving a rebound after a steep selloff over financing and debt concerns. Traders are split between expecting a recovery or short squeeze and warning that the companys heavy obligations and insider selling remain significant risks.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS CEO Angelos Stergious anniversary post about the companys next chapter fueled speculation about upcoming clinical news or a possible buyout, though some traders dismissed it as a routine message. The debate centers on the still-unconfirmed 80th-event trigger for the Phase 3 REGAL trial: bulls view the prolonged wait as potentially encouraging for patient survival, while skeptics note that the blinded trials timeline alone does not establish efficacy.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are drawing attention for a sharp pullback, with traders repeatedly pointing to insider selling and weak price action; some also cite higher oil prices and broader macro pressure as headwinds. Bulls argue the companys growth and valuation support a recovery, while bears see more downside and question managements approach to shareholder returns.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention after a steep selloff, with traders citing upcoming IPO lockup share releases, a reported TD Cowen downgrade, and concerns about valuation, customer concentration and the companys ability to scale. The community is split between expecting more selling and buying the dip, while some attribute the weakness to a broader AI and semiconductor pullback.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

X-Energys small modular reactor buildout is drawing attention around updates on its Oak Ridge fuel facility and nuclear-grade graphite supply, against a broader AI and data-center power-demand theme. Traders are broadly bullish on the long-term opportunity and Amazons backing, while some remain cautious about execution timelines and the stocks sharp volatility.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Bernsteins upgrade of Datadog to Outperform, citing AI-driven demand for its observability offerings, is drawing attention as shares rebound. Traders are weighing that bullish AI-growth case against concerns about the stocks rich valuation and recent software-sector volatility.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is drawing attention for its struggle to hold above a key resistance area, with traders positioning ahead of the upcoming earnings report. Bulls see recent support as a possible breakout setup, while bears point to repeated rejections and difficulty sustaining a move higher.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iBio, Inc. (NASDAQ:IBIO) Given Consensus Recommendation of "Buy" by Analysts

Shares of iBio, Inc. (NASDAQ:IBIO - Get Free Report) have been given an average recommendation of "Buy" by the six brokerages that are covering the firm, MarketBeat reports. One research analyst has...

iBio (IBIO) Projected to Post Quarterly Earnings on Friday

iBio (NASDAQ:IBIO) will be releasing its Q3 2026 earnings before the market opens on Friday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-1-ibio-inc-stock-3...

iBio (NASDAQ:IBIO) Earns Buy Rating from Chardan Capital

Chardan Capital restated a "buy" rating and issued a $5.00 target price on shares of iBio in a report on Thursday...

iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close Trust Gap

iBio (NASDAQ:IBIO) is seeking to narrow what it views as a growing trust gap between the promise of generative AI in drug discovery and the high cost and long timelines of bringing a drug to market...

IBIO Stock Is Soaring Today After iBio's Muscle-Preserving Drug Receives Approval For Human Trial In Australia

Equity

iBio stated that IBIO-600 has been approved by Australia’s Therapeutic Goods Administration to initiate a Phase 1 study in overweight and obese adult participants.

iBio, Inc. (NASDAQ:IBIO) Given Average Recommendation of "Buy" by Analysts

iBio, Inc. (NASDAQ:IBIO - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are presently covering the company, Marketbeat.com reports. One research...

iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded iBio from a "sell" rating to a "hold" rating in a report on Saturday...

Insider Buying: iBio (NASDAQ:IBIO) CFO Buys 24,835 Shares of Stock

iBio, Inc. (NASDAQ:IBIO - Get Free Report) CFO Felipe Duran bought 24,835 shares of the stock in a transaction dated Thursday, March 19th. The stock was purchased at an average price of $2.02 per...

iBio (NASDAQ:IBIO) CFO Felipe Duran Acquires 24,835 Shares

iBio, Inc. (NASDAQ:IBIO - Get Free Report) CFO Felipe Duran bought 24,835 shares of the company's stock in a transaction dated Thursday, March 19th. The stock was purchased at an average price of...

Martin Brenner Purchases 12,336 Shares of iBio (NASDAQ:IBIO) Stock

iBio, Inc. (NASDAQ:IBIO - Get Free Report) insider Martin Brenner purchased 12,336 shares of the stock in a transaction dated Thursday, March 19th. The stock was purchased at an average cost of $2.02...

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

iBio Inc

Bullish Sentiment

<ul class="summary-bullets"><li>iBio stated that it expects to dose the first participant in Australia with IBIO-600 in the second quarter.</li><li>The company’s previously announced pre-clinical studies showed that IBIO-600 demonstrated a pharmacologic activity and an extended half-life of 40–52 days following a single administration in non-human primates.</li><li>iBio stated that it also observed an increase of over 5.1% in lean muscle mass during its pre-clinical studies.</li></ul>iBio Inc. (IBIO) shares gained nearly 10% in Wednesday’s pre-market trade after the company announced that its muscle-preserving drug has received approval for the first in-human trial in Australia.iBio stated that IBIO-600 has been approved by Australia’s Therapeutic Goods Administration (TGA) to initiate a Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in overweight and obese adult participants.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBIO">iBio</a> trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">First Participant Expected To Be Dosed In Q2</h2>iBio stated that it expects to dose the first participant in Australia with IBIO-600 in the second quarter (Q2).“While GLP-1 therapies have transformed the treatment landscape, significant gaps remain, particularly around the loss of muscle mass. We believe IBIO-600 has the potential to address this unmet need,” said iBio CEO Martin Brenner.iBio’s previously announced pre-clinical studies showed that IBIO-600 demonstrated a pharmacologic activity and an extended half-life of 40–52 days following a single administration in non-human primates.The company also observed an increase of over 5.1% in lean muscle mass during its pre-clinical studies.“These findings, observed alongside reductions in fat mass and durable effects over time, support the advancement of IBIO-600 into clinical development,” the company added.<h2 class="st-heading-2">What Does IBIO-600 Do?</h2>IBIO-600 is a long-acting monoclonal antibody that targets myostatin and GDF11, which are proteins that inhibit skeletal muscle growth.It is designed to help preserve lean muscle and improve body composition in patients with obesity. iBio stated that it has the potential to be used alongside GLP-1 treatments to counter muscle loss during weight reduction.<a href="https://stocktwits.com/symbol/IBIO">IBIO stock</a> is up 9% year-to-date and 40% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 31% over the past 12 months, while the Vanguard Extended Market Index Fund ETF (VXF) is up 36% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dal-stock-soars-delta-air-lines-q1-results-beat-expectations/cZJODXcRIqr">DAL Stock Soars As Delta Air Lines Beats Q1 Expectations, CEO Says ‘Demand Remains Strong’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.7541
Prev Close	$0.7663
Open	$0.7541
Dividend Yield	0.00%
50-Day Moving Average	$1.23
Beta	1.55
Avg. Volume	595,912.42
PE Ratio	-1.69

52-Week High	$3.82
52-Week Low	$0.7328
Market Capitalization	$46.63M
EPS (Annual)	-$0.3176
Price to Book	0.50
Revenue Per Employee	$4,347.83

Feed

News

Sentiment

Fundamentals

Info

IBIO Fundamentals